As of Friday close, Novartis AG’s (NYSE:NVS) stock was down -$0.71, moving down -0.70 percent to $101.02. The average number of shares traded per day over the past five days has been 795,780 shares. 1 time new highs have been achieved over the past 5 days, with a -$2.57 fall in that time frame. In the last twenty days, the average volume was 1,025,275, while in the previous 50 days, it was 1,598,444.
Since last month, NVS stock retreated -3.91%. Shares of the company fell to $100.92 on 08/18/23, the lowest level in the past month. A 52-week high of $105.61 was reached on 07/21/23 after having rallying from a 52-week low of $74.09. Since the beginning of this year, NVS’s stock price has risen by 11.35% or $10.30, and marked a new high 17 times. However, the stock has declined by -4.35% since its 52-week high.
Valuation Metrics
Right now, Novartis AG (NVS) has a P/E ratio of about 28.15. The stock’s beta is 0.54. Besides these, the trailing price-to-sales (P/S) ratio of 4.33, the price-to-book (PB) ratio of 4.06, and the price-to-cash flow ratio of 18.10 may also be considered.
The latest dividend of $3.4694 per share was paid out, which is 195.27% more than last year’s $1.1750. On Thursday February 2 2023, a $2.2944 dividend increase was announced.
Financial Health
In the recent quarter, Novartis AG’s quick ratio stood at 0.80, while its current ratio was 1.00, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the recent quarter was 0.38, and the total debt-to-equity ratio was 0.55. On the profitability front, the trailing twelve-month gross margin is 71.10% percent. In the recent year, EBITDA margin amounted to 35.04%, whereas operating margins totaled 18.70%. Based on annual data, NVS earned $36.34 billion in gross profit and brought in $51.83 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 8.90%. Return on equity (ROE) for the past 12 months was 13.70%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. NVS’s revenue fell -2.02% during the quarter, while net income inched up to $51.83 billion. During the quarter, the company generated $4.77 billion in EBITDA. The liabilities of Novartis AG were 59.05 billion at the end of its most recent quarter, and its total debt was $28.34 billion.
Technical Picture
This quick technical analysis looks at Novartis AG’s (NVS) price momentum. With a historical volatility rate of 5.96%, the RSI 9-day stood at 33.99% on 18 August.
With respect to its five-day moving average, the current Novartis AG price is down by -2.48% percent or -$2.57. At present, NVS shares trade -3.80% below its 20-day simple moving average and +11.90% percent above its 100-day simple moving average. However, the stock is currently trading approximately +2.56% above its SMA50 and +24.52% above its SMA200.
Stochastic coefficient K was 13.87% and Stochastic coefficient D was 26.21%, while ATR was 1.01. Given the Stochastic reading of 2.66% for the 14-day period, the RSI (14) reading has been calculated as 42.78%. As of today, the MACD Oscillator reading stands at -1.06, while the 14-day reading stands at -1.01.
Analyst Ratings
HSBC Securities launched its rating on Novartis AG (NYSE: NVS) to a Buy in a note to investors on July 14, 2023. Novartis AG (NVS) has been rated Overweight by analysts. According to 2 brokerage firms, NVS is a sell, and 12 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Novartis AG stock as buy, with 9 recommending it as overweight.
With a median target price of $116.94, the current consensus forecast for the stock is $93.07 – $128.26. Based on these forecasts, analysts predict Novartis AG (NVS) will achieve an average price target of $115.86.
